On October 16, 2024 Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, reported the company will deliver a poster presentation highlighting preclinical data on SKY-1214 at the 36th European Organization for Research and Treatment of Cancer (EORTC)-National Cancer Institute (NCI)-American Association for Cancer Research (AACR) (Free AACR Whitepaper) Molecular Targets and Cancer Therapeutics Symposium ("EORTC-NCI-AACR") to be held from October 23-25, 2024 in Barcelona, Spain (Press release, Skyhawk Therapeutics, OCT 16, 2024, View Source [SID1234647230]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SKY-1214 is an oral RNA splicing modulator developed through the company’s novel RNA-splicing platform and being developed for difficult to treat multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). SKY-1214 targets FANCL/FANCI, critical components of the Fanconi anemia DNA damage repair pathway, which MM and NHL cells use to maintain their genome integrity.

Details of the data presentation are as follows:

Title: "Preclinical characterization of SKY-1214, a small molecule splicing

modulator of Fanconi Anemia pathway members for the treatment of

multiple myeloma and non-Hodgkin’s lymphoma"

Session Type: New Drugs

Poster Number: #PB104

Date: Wednesday, 23 October 2024

Location: Exhibition Hall

Presenter: Simone Rauch, PhD, Skyhawk Therapeutics